Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has The Epithelial Ovarian Cancer Market Size Shifted, And What Is the Outlook Through 2034?
The market for epithelial ovarian cancer has experienced a swift expansion in the past few years. It is projected to increase from $2.08 billion in 2024 to $2.41 billion in 2025, growing at a compound annual growth rate (CAGR) of 16.0%. The growth seen in the historic period can be traced back to factors such as the heightened demand for bespoke cancer treatments, an escalation in worldwide healthcare spending, a surge in the requirement for minimally invasive surgical procedures, an increase in the population of ovarian cancer survivors, burgeoning demand for gene therapy approaches, and a rising need for palliative care services.
The market size for epithelial ovarian cancer is projected to experience significant growth in the approaching years, with estimations suggesting it could reach $4.36 billion by 2029, reflecting a compound annual growth rate (CAGR) of 16.0%. The forecasted growth within this timeframe can be credited to a surge in ovarian cancer cases, an aging demographic, enhanced ovarian cancer awareness, a rise in cancer research funding, and amplified governmental efforts to mitigate cancer. Key trends during the forecasted period encompass advancements in medical imaging technology, the unveiling of innovative molecular diagnostic tools, partnerships amongst pharmaceutical corporations, the fast-paced integration of AI and machine learning in diagnoses, and the increasing implementation of robotic surgeries.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20778&type=smp
What External and Internal Drivers Are Contributing to the Growth of theEpithelial Ovarian Cancer Market?
The epithelial ovarian cancer market’s growth is anticipated to be spurred by the rising incidence of ovarian cancer. Ovarian cancer primarily affects the epithelial cells that form the ovaries’ surface. The key reasons behind the escalating occurrence of ovarian cancer include an aging population, enhanced awareness, and increased detection rates, in addition to genetic and lifestyle factors. To deal with the most frequent and aggressive type of ovarian cancer, treatment for epithelial ovarian cancer is essential. This treatment aims to target the malignant cells to enhance survival rates and patient results. For example, the World Ovarian Cancer Coalition, a non-profit organization located in Canada, projected in February 2024 that by 2050, there will be a 55% rise in the global number of women diagnosed with ovarian cancer, attaining 503,448 cases. It’s forecasted that annual deaths due to ovarian cancer will escalate to 350,956, recording an approximately 70% increase from 2022. Consequently, the escalating incidence of ovarian cancer is predicted to propel the epithelial ovarian cancer market in the future.
What Segment Types Define the Epithelial Ovarian Cancer Market Structure?
The epithelial ovarian cancermarket covered in this report is segmented –
1) By Type Of Treatment: Chemotherapy; Targeted Therapy; Immunotherapy; Hormonal Therapy; Surgery
2) By Drug Class: Platinum-based Chemotherapy Drugs; Poly(ADP-ribose) Polymerase Inhibitors; Bevacizumab; Chemotherapeutic Agents
3) By Stage Of Cancer: Early Stage; Advanced Stage
4) By Diagnosis Method: Imaging; Biopsy; Blood Tests
5) By End User: Hospitals; Clinics; Diagnostic Laboratories
Subsegments:
1) By Chemotherapy: Platinum-Based Chemotherapy; Non-Platinum Chemotherapy; Combination Chemotherapy
2) By Targeted Therapy: Monoclonal Antibodies; PARP Inhibitors; Angiogenesis Inhibitors; Other Targeted Agents
3) By Immunotherapy: Checkpoint Inhibitors; Cancer Vaccines; Adoptive T-Cell Therapy
4) By Hormonal Therapy: Selective Estrogen Receptor Modulators (SERMs); Aromatase Inhibitors; Progestins
5) By Surgery: Debulking Surgery; Oophorectomy; Hysterectomy; Other Surgical Procedures
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=20778&type=smp
Which Geographic Areas Hold the Strongest Growth Potential in the Epithelial Ovarian Cancer Market?
North America was the largest region in the epithelial ovarian cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the epithelial ovarian cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Long-Term Trends Are Transforming the Competitive Landscape of the Epithelial Ovarian Cancer Market?
The focus for leading firms in the epithelial ovarian cancer market is on developing novel treatment solutions, such as FRa-directed antibody-drug conjugates (ADCs), which specifically target overexpressed folate receptor-alpha on cancer cells and deliver powerful cytotoxic agents, thus reducing damage to healthy tissues. An FRa-directed ADC is a cancer treatment that links an antibody that is specific to the folate receptor-alpha (FRa) to a cytotoxic drug, facilitating direct delivery of the drug to cancer cells that express this receptor. For example, in November 2024, US-based biopharmaceutical firm, AbbVie Inc., secured European Commission approval for ELAHERE (mirvetuximab soravtansine). This is a targeted treatment for adult patients with platinum-resistant, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer that is folate receptor-alpha (FRa) positive. ELAHERE offers a fresh, effective treatment alternative for patients who have undergone up to three prior systemic regimes. It targets a biomarker present in around a third of ovarian cancer patients, which enhances survival probability, and improves life quality. This approval also includes a companion diagnostic for identifying eligible patients.
View the full report here:
https://www.thebusinessresearchcompany.com/report/epithelial-ovarian-cancer-global-market-report
What Is the Definition of the Epithelial Ovarian Cancer Market?
Epithelial ovarian cancer is the most common type of ovarian cancer, originating from the epithelial cells that form the outer layer of the ovary. Most often, it affects women over fifty. EOC is often asymptomatic in its early stages, leading to late diagnoses when the disease has already progressed. Symptoms, when present, may include abdominal bloating, pelvic pain, frequent urination, and changes in bowel habits.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20778
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model